Daclatasvir + Sofosbuvir interactions
Checked as Daclatasvir + Sofosbuvir in this data source.
Full monograph for Daclatasvir + SofosbuvirCheck it against another medicine
Medicines
183 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amiodarone Hydrochloridevia Sofosbuvir | Major | Others | Severe, life-threatening, symptomatic bradycardia has been reported during coadministration of amiodarone with ledipasvir-sofosbuvir or with sofosbuvir taken… | 8 sources — open the full entry |
| Apalutamidevia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral…2 documented mechanisms | 17 sources — open the full entry |
| Bosentan Monohydratevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasonevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Carbamazepinevia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting…2 documented mechanisms | 11 sources — open the full entry |
| Cenobamatevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Ceritinibvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Ciprofloxacin + Dexamethasonevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by…2 documented mechanisms | 5 sources — open the full entry |
| Clarithromycinvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Colchicinevia Daclatasvir | Major | Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced… | 78 sources — open the full entry |
| Dexamethasonevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Dexamethasone + Chloramphenicolvia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by…2 documented mechanisms | 5 sources — open the full entry |
| Dexamethasone + Levofloxacinvia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acidvia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphatevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Dexamethasone + Tobramycinvia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Efavirenzvia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Eluxadolinevia Daclatasvir | Major | Metabolism | Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline… | 8 sources — open the full entry |
| Enzalutamidevia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral…2 documented mechanisms | 17 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycinvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Fosphenytoin Sodiumvia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting…2 documented mechanisms | 11 sources — open the full entry |
| Gatifloxacin + Dexamethasonevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Itraconazolevia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Ketoconazolevia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleoveravia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapinevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycinvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Lopinavir + Ritonavirvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Lorlatinibvia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral…2 documented mechanisms | 13 sources — open the full entry |
| Mifepristonevia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Mifepristone + Misoprostolvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Morphine Sulfatevia Daclatasvir | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including… | 7 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasonevia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Nelfinavirvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Nirmatrelvir + Ritonavirvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Oxcarbazepinevia Sofosbuvir | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Phenobarbitalvia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting…2 documented mechanisms | 11 sources — open the full entry |
| Phenytoin Sodiumvia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting…2 documented mechanisms | 11 sources — open the full entry |
| Posaconazolevia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Primidonevia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting…2 documented mechanisms | 11 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycinvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
| Relugolixvia Daclatasvir | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Relugolix + Estradiol + Norethindronevia Daclatasvir | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Rifampicinvia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given…2 documented mechanisms | 10 sources — open the full entry |
| Rifampicin + Isoniazidvia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given…2 documented mechanisms | 10 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutolvia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given…2 documented mechanisms | 10 sources — open the full entry |
| Sotorasibvia Daclatasvir | Major | Metabolism | Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by… | 2 sources — open the full entry |
| Tucatinibvia Sofosbuvir, Daclatasvir | Major | Absorption · Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by…2 documented mechanisms | 5 sources — open the full entry |
| Venetoclaxvia Daclatasvir | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. | 5 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycinvia Daclatasvir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by… | 4 sources — open the full entry |
Conditions
Conditions in which Daclatasvir + Sofosbuvir needs care, as documented in this source.
Fibrosis
MajorIn clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates. In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir. Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up. Consider appropriate management for patients with HBV infection as clinically indicated.
1 source
- "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb (2015):
IMMUNE SUPPRESSION
MajorHBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive). HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients. All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy. Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.
7 sources
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
- "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences (2014):
- "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC (2022):
- "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):
- "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences (2016):
- "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences (2017):
- "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical (2017):
Hepatic Insufficiency
ModerateSofosbuvir is extensively metabolized in the liver. The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis. No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).
1 source
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
Kidney Diseases
ModerateThe safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis. No dosage recommendation can be given for patients with severe renal impairment or ESRD. No dosage adjustment is necessary for patients with mild or moderate renal impairment.
1 source
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
Therapeutic duplication
Drug classes that overlap with Daclatasvir + Sofosbuvir, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
ns5a inhibitors
The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NS5A inhibitors' category.
Example product in the source data (US market): Ombitasvir/paritaprevir/ritonavir
ns5a inhibitors
The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NS5A inhibitors' category.
Example product in the source data (US market): Zepatier
ns5a inhibitors
The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NS5A inhibitors' category.
Example product in the source data (US market): Dasabuvir/ombitasvir/paritaprevir/ritonavir
ns5a inhibitors
The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'NS5A inhibitors' category.
Example product in the source data (US market): Sofosbuvir/velpatasvir/voxilaprevir